GLP-1 users emerge as a pivotal voting bloc ahead of the midterms
New polling shows that Americans taking GLP-1 drugs like Ozempic form a growing political constituency that both parties are racing to court before the midterm elections.
Recent Cygnus polling identifies a sizable group of Americans on GLP-1 drugs such as Ozempic and Wegovy, turning them into a new electoral force as the midterms approach. Physicians note that users report better energy, mobility and health markers, which in turn influences their expectations of government action on preventive care. Advocates argue that this cohort, often working-age parents concerned about childhood obesity, seeks policies that lower drug costs, expand access and prioritize prevention over chronic-disease management.
The piece argues Republicans have a strategic opening to promote competition, patient-centered care and reduced regulation, contrasting this with a Democratic stance described as more regulatory.
Why it matters
A fast-growing health-focused voter group could sway the outcome of the upcoming midterm elections.
In this story